Compile Data Set for Download or QSAR
Report error Found 150 Enz. Inhib. hit(s) with all data for entry = 3353
TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397684(US9994547, Example 53 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 2.51nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397657(US9994547, Example 26 | (R)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 3.16nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397717(US9994547, Example 86 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 3.98nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397772(US9994547, Example 141 | (R)-N-(5-(6-cyano-5-((2-(...)
Affinity DataIC50: 5.01nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397638(US9994547, Example 7 | (S)-N-(5-(4-cyano-3-((1-(di...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397665(US9994547, Example 34 | (S)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397679(US9994547, Example 48 | (R)-N-(5-(6-cyano-5-((2-ox...)
Affinity DataIC50: 6.31nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397632(US9994547, Example 1 | (S)-N-(5-(4-cyano-3-((1-(di...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397637(US9994547, Example 6 | N-(5-(4-cyano-3-((1-(dimeth...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397639(US9994547, Example 8.0)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397750(US9994547, Example 119 | N-(5-(6-cyano-5-(((2S)-1-...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397777(US9994547, Example 146 | N-(5-(6-cyano-5-(((S)-1-(...)
Affinity DataIC50: 7.94nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397643(US9994547, Example 12 | (S)-N-(5-(4-cyano-3-((1-(e...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397677(US9994547, Example 46 | N-(5-(6-cyano-5-((1-((2,2-...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397685(US9994547, Example 54 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 10nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397634(US9994547, Example 3.0)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397681(US9994547, Example 50 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397720(US9994547, Example 89 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 12.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397660(US9994547, Example 29 | N-(5-(4-cyano-3-((1-((2-hy...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397672(US9994547, Example 41 | N-(5-(6-cyano-5-((1-(methy...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397703(US9994547, Example 72 | N-(5-(6-cyano-5-((2-((2,2-...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397712(US9994547, Example 81 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397713(US9994547, Example 82 | N-(5-(6-cyano-5-((2-((2,2-...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397727(US9994547, Example 96 | (S)-N-(5-(6-cyano-5-((2-ox...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397738(US9994547, Example 107 | (1R,2R)-N-(5-(6-cyano-5-(...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397781(US9994547, Example 150 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 15.8nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397650(US9994547, Example 19 | (S)-N-(5-(4-cyano-3-((1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397654(US9994547, Example 23 | (S)-N-(5-(4-cyano-3-((1-(d...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397674(US9994547, Example 43 | N-(5-(6-cyano-5-((1-((cyan...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397678(US9994547, Example 47 | N-(5-(6-cyano-5-((1-((2-fl...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397687(US9994547, Example 56 | (S)-N-(5-(6-cyano-5-((1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397700(US9994547, Example 69 | N-(5-(6-cyano-5-(((2S)-1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397722(US9994547, Example 91 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397739(US9994547, Example 108 | (1R,2S)-N-(5-(6-cyano-5-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397743(US9994547, Example 112 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397745(US9994547, Example 114 | (S)-N-(5-(6-cyano-5-((1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397760(US9994547, Example 129 | US9994547, Example 135 | ...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397770(US9994547, Example 139 | N-(5-(6-cyano-5-(((S)-1-(...)
Affinity DataIC50: 20nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397686(US9994547, Example 55 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397719(US9994547, Example 88 | N-(5-(6-cyano-5-(((S)-1-((...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397744(US9994547, Example 113 | N-(5-(6-cyano-5-((2-((2S,...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397757(US9994547, Example 126 | N-(5-(4-cyano-3-((2-(meth...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397760(US9994547, Example 129 | US9994547, Example 135 | ...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397767(US9994547, Example 136 | (S)-N-(5-(4-cyano-3-((1-(...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397768(US9994547, Example 137 | (S)-N-(5-(4-cyano-3-((1-(...)
Affinity DataIC50: 25.1nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397649(US9994547, Example 18 | N-(5-(4-cyano-3-((1-(dimet...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397671(US9994547, Example 40 | N-(5-(6-cyano-5-((2-(methy...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397676(US9994547, Example 45 | (R)-N-(5-(6-cyano-5-((2-(2...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397695(US9994547, Example 64 | N-(5-(6-cyano-5-((2-oxo-2-...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

TargetSerine/threonine-protein kinase TBK1(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM397741(US9994547, Example 110 | N-(5-(6-cyano-5-((2-((2-h...)
Affinity DataIC50: 31.6nMAssay Description:TBK1 inhibition is determined using a 384 well μlate format in buffer containing 20 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EDTA, 0.01% Brij-L23, 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 150 total ) | Next | Last >>
Jump to: